Traws Pharma
TRAW
13 hedge funds and large institutions have $6.74M invested in Traws Pharma in 2019 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 0 closing their positions.
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
8% more funds holding
Funds holding: 12 → 13 (+1)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% less ownership
Funds ownership: 0.11% → 0.11% (-0%)
12% less capital invested
Capital invested by funds: $7.63M → $6.74M (-$895K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$92.3K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$62K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$44.1K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$23.4K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$6.88K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$28.9K |
| 2 |
TCP
Tyndall Capital Partners
New York
|
-$11K |
| 3 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
-$2.75K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
6CM
1
683 Capital Management
New York
| $2.75M | – | – | – |
|
|
TCP
2
Tyndall Capital Partners
New York
| $2.32M | -$11K | -8 | -0.4% |
|
3
Point72 Asset Management
Stamford,
Connecticut
| $689K | – | – | – |
|
|
KC
4
Kepos Capital
New York
| $365K | – | – | – |
|
|
5
Vanguard Group
Malvern,
Pennsylvania
| $189K | +$92.3K | +67 | +61% |
|
|
6
Geode Capital Management
Boston,
Massachusetts
| $135K | +$44.1K | +32 | +34% |
|
|
7
Renaissance Technologies
New York
| $112K | -$28.9K | -21 | -17% |
|
|
8
Dimensional Fund Advisors
Austin,
Texas
| $111K | +$23.4K | +17 | +20% |
|
|
9
Citadel Advisors
Miami,
Florida
| $48K | +$62K | +45 | New |
|
|
10
UBS Group
Zurich,
Switzerland
| $10K | +$6.88K | +5 | +100% |
|
|
PFGIA
11
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| $3K | -$2.75K | -2 | -40% |
|
12
Morgan Stanley
New York
| $2K | – | – | – |
|
|
WCG
13
Weaver Consulting Group
Huntington Beach,
California
| $1K | – | – | – |
|
TRAW Hedge Fund Activity: Q2 2019 in Review
13 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q2 2019, worth a combined $6.74M — down 12% from $7.63M a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new TRAW positions and 0 closed out — a net gain of 1 holder — while 4 added to existing stakes and 3 trimmed.
The largest buyer was Vanguard Group, adding an estimated $92.3K. The largest seller was Renaissance Technologies, cutting an estimated $28.9K.
- 13 institutional investors held Traws Pharma (TRAW) as of Q2 2019, up from 12 in Q1 2019.
- Funds reported $6.74M of Traws Pharma stock for Q2 2019, down 12% quarter-over-quarter.
- 1 fund opened new Traws Pharma positions in Q2 2019 and 0 closed out, a net change of +1 holder.
- The largest Traws Pharma buyer in Q2 2019 was Vanguard Group, an estimated $92.3K added.
- The largest Traws Pharma seller in Q2 2019 was Renaissance Technologies, an estimated $28.9K sold.
Based on aggregated 13F filings for Q2 2019.